Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Sarcoma 1Plasma cell 1Genitourinary 1Classical hematology 1

Conditions

Prostatic Neoplasms 118Urinary Bladder Neoplasms 27Carcinoma, Renal Cell 25Kidney Neoplasms 19Neoplasms 14Neoplasm Metastasis 9Breast Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Prostatic Hyperplasia 5Pain 5Lung Neoplasms 5Liver Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Carcinoma, Hepatocellular 4Urologic Neoplasms 3Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Multiple Myeloma 3Kidney Diseases 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Wilms Tumor 2Uterine Cervical Neoplasms 2Tobacco Use Disorder 2Small Cell Lung Carcinoma 2Prostatic Diseases 2Prostate Cancer Metastatic 2Pancreatic Neoplasms 2

Interventions

Zoledronic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Bone Diseases, Metabolic × Genitourinary × Clear all
NCT00063609 2017-09-13

The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

Novartis

Phase 4 Completed
200 enrolled
Genitourinary

Bone Diseases, Metabolic, Osteoporosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡